HK1008827A1 - Monoclonal antibodies tos stem cell factor receptors - Google Patents

Monoclonal antibodies tos stem cell factor receptors

Info

Publication number
HK1008827A1
HK1008827A1 HK98109574A HK98109574A HK1008827A1 HK 1008827 A1 HK1008827 A1 HK 1008827A1 HK 98109574 A HK98109574 A HK 98109574A HK 98109574 A HK98109574 A HK 98109574A HK 1008827 A1 HK1008827 A1 HK 1008827A1
Authority
HK
Hong Kong
Prior art keywords
monoclonal antibodies
stem cell
tos
cell factor
factor receptors
Prior art date
Application number
HK98109574A
Other languages
English (en)
Inventor
Nancy Lin
Virginia C Broudy
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of HK1008827A1 publication Critical patent/HK1008827A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK98109574A 1991-04-05 1998-07-31 Monoclonal antibodies tos stem cell factor receptors HK1008827A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68124591A 1991-04-05 1991-04-05
PCT/US1992/002674 WO1992017505A1 (en) 1991-04-05 1992-04-03 Monoclonal antibodies to stem cell factor receptors

Publications (1)

Publication Number Publication Date
HK1008827A1 true HK1008827A1 (en) 1999-05-21

Family

ID=24734435

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98109574A HK1008827A1 (en) 1991-04-05 1998-07-31 Monoclonal antibodies tos stem cell factor receptors

Country Status (10)

Country Link
US (5) US5489516A (ja)
EP (1) EP0578774B1 (ja)
JP (1) JP3213314B2 (ja)
AT (1) ATE169031T1 (ja)
CA (1) CA2107553C (ja)
DE (1) DE69226431T2 (ja)
DK (1) DK0578774T3 (ja)
ES (1) ES2118820T3 (ja)
HK (1) HK1008827A1 (ja)
WO (1) WO1992017505A1 (ja)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20002145B (en) * 1989-10-16 2000-06-25 Amgen Inc Us Stem Cell Factor
US7144731B2 (en) * 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
CA2107553C (en) * 1991-04-05 2001-07-31 Nancy Lin Monoclonal antibodies to stem cell factor receptors
EP0548867A2 (en) * 1991-12-23 1993-06-30 Yeda Research And Development Co. Ltd. Soluble stem cell factor (SFC)-receptor
FR2700471B1 (fr) * 1993-01-21 1995-04-07 Pasteur Merieux Serums Vacc Utilisation d'anticorps monoclonaux anti-LFA-1 pour la préparation d'un médicament destiné à prévenir le rejet des greffes d'organes solides et médicaments obtenus.
US5911988A (en) * 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
US5824789A (en) * 1995-06-07 1998-10-20 Systemix, Inc. Human growth factors, nucleotide sequence encoding growth factors, and method of use thereof
DE19600589C1 (de) 1996-01-10 1997-01-16 Univ Eberhard Karls Antikörper A3C6E2
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
EP0941120A4 (en) * 1996-11-05 2004-08-18 Bristol Myers Squibb Co BRANCHED PEPTIDLINKERS
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6737249B1 (en) * 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
SE9803712L (sv) * 1998-10-29 1999-12-20 Henrik Willers Förfarande och anordning för förankring av en boj
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
AU5003001A (en) * 2000-03-06 2001-09-17 Univ Kentucky Res Found Methods to impair hematologic cancer progenitor cells and compounds related thereto
US20050064587A1 (en) * 2001-09-07 2005-03-24 Lawrence Rosenberg Pancreatic small cells and uses thereof
US7754155B2 (en) * 2002-03-15 2010-07-13 Ross Amelia A Devices and methods for isolating target cells
US20030175818A1 (en) * 2002-03-15 2003-09-18 Ross Amelia A. Devices and methods for isolating and recovering target cells
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
ES2438965T3 (es) * 2002-04-23 2014-01-21 Roger Williams Hospital Composiciones y métodos para administrar células madre
AU2003289116A1 (en) * 2002-12-16 2004-07-09 Canon Kabushiki Kaisha Pattern identification method, device thereof, and program thereof
EP1711159B1 (en) 2003-12-30 2013-03-20 Durect Corporation Solid implants containing a block copolymer for controlled release of a gnrh compound
US7790679B2 (en) 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
TWI395754B (zh) * 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
WO2008030538A2 (en) * 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Cancer stem cell-targeted cancer therapy
PT3255061T (pt) 2006-11-03 2021-07-26 Univ Leland Stanford Junior Imunodepleção seletiva de nicho de células estaminais endógenas para enxerto
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
DK3241558T3 (da) 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc Højopløselige leptiner
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
US9334332B2 (en) 2012-07-25 2016-05-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
US9498543B2 (en) 2013-03-15 2016-11-22 Novartis Ag Antibody drug conjugates
WO2015050959A1 (en) * 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
US10889646B2 (en) 2015-03-25 2021-01-12 Children's Hospital Medical Center Use of KIT inhibitors to condition subjects for a hematopoietic stem cell (HSC) transplantation
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. CELL EXPANSION
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
JP7062647B2 (ja) 2016-06-17 2022-05-06 マジェンタ セラピューティクス インコーポレイテッド Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法
MX2019008205A (es) 2017-01-20 2020-01-23 Magenta Therapeutics Inc Composiciones y metodos para el agotamiento de células cd137+.
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656842A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
JP2024511064A (ja) 2021-03-23 2024-03-12 テルモ ビーシーティー、インコーポレーテッド 細胞捕獲及び増殖
WO2023111311A1 (en) 2021-12-16 2023-06-22 Universität Basel Discernible cell surface protein variants of cd117 for use in cell therapy
WO2024008910A1 (en) 2022-07-07 2024-01-11 Cimeio Therapeutics Ag Antibodies targeting cd117

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965204A (en) * 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5081030A (en) * 1989-04-25 1992-01-14 The Johns Hopkins University Release of cells from affinity matrices
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
CA2107553C (en) * 1991-04-05 2001-07-31 Nancy Lin Monoclonal antibodies to stem cell factor receptors

Also Published As

Publication number Publication date
JPH06506833A (ja) 1994-08-04
US5922847A (en) 1999-07-13
DK0578774T3 (da) 1999-04-26
CA2107553C (en) 2001-07-31
WO1992017505A1 (en) 1992-10-15
EP0578774A1 (en) 1994-01-19
US5919911A (en) 1999-07-06
EP0578774B1 (en) 1998-07-29
EP0578774A4 (en) 1995-11-15
JP3213314B2 (ja) 2001-10-02
ES2118820T3 (es) 1998-10-01
US5489516A (en) 1996-02-06
DE69226431D1 (de) 1998-09-03
CA2107553A1 (en) 1992-10-06
US5906938A (en) 1999-05-25
ATE169031T1 (de) 1998-08-15
DE69226431T2 (de) 1999-04-22
US20020018775A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
HK1008827A1 (en) Monoclonal antibodies tos stem cell factor receptors
BG102172A (en) New stable medicamentous compositions for the preparation of propellant-free aerosols
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
UA39168C2 (uk) Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі
MY122262A (en) Lh-rh peptide analogues their uses and pharmaceutical compositions containing them
IL122370A (en) Monkey monoclonal antibodies to human B7 antigens and pharmaceutical compositions containing them
ES8706132A1 (es) Un procedimiento para la preparacion de analogos de benzodiazepina
IL141082A0 (en) Peptide antagonists of zonulin and pharmaceutical compositions containing the same
IL78444A0 (en) Human gamma interferon-specific receptor protein,antibody against said protein,methods for obtaining said protein and said antibody and compositions containing said protein and antibody
AU2002364082A1 (en) Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
IL103510A0 (en) Pharmaceutical compositions containing antibodies for causing immunosuppression
ES8704946A1 (es) Un procedimiento para la preparacion de triazolobenzodiazefinas.
YU394A (sh) Novi peptidi koji deluju kao antagonisti opijatskih receptora i postupci za njihovu izradu
GB8702689D0 (en) Monoclonal human antibody compositions
EP1491632A3 (en) Anti-alphavbeta3 humanized monoclonal antibodies
PT85490A (en) Process for the preparation of specific monoclonal antibodies of apolipoprotein-b and essay processes for the determination o the above mentioned apolipoprotein
YU13392A (sh) ANTITELA NA HUMANI RECEPTOR ZA IgE
BR9305557A (pt) Anticorpos monoclonais humanos anti Rhesus-D e composiçao farmacêutica que os contém
DE59812529D1 (de) Monoklonaler Antikörper 4G8B4B12 gegen humanes FLT3/FLK2
GB2254326B (en) Monoclonal antibodies produced by in vitro immunization of lymphocytes
NZ337601A (en) Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics by inhibiting IgE expression
PT85247A (en) Process for the preparation of monoclonal antibodies to pseudomonas aeroginosa flagella and of compositions containing the same
EP0722489A4 (en) MONOCLONAL ANTIBODIES THAT DETECT FLK-2 RECEPTORS AND THE ISOLATION OF PRIMITIVE HEMATOPOIETIC STEM CELL POPULATIONS
MD553F1 (en) New derivatives of pyrazolepyrimidine receptors antagonists of angiotensine II, realization processes and pharmaceutical compositions

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100403